Kornimate/medical-research-clean huggingface dataset:
evaluation of the effect of citicoline and docosahexaenoic acid (dha) on the visual function of patients with glaucoma

Conditions: Glaucoma

Summary: pilot, single-blind, randomized and controlled study to evaluate the changes produced in the visual function of patients with glaucoma after oral administration for 3 months of citicoline and docosahexaenoic acid (dha) vs citicoline and docosahexaenoic acid (dha) vs vitamin c.


Eligibility criteria:
inclusion criteria: 1. patients with chronic, primary or secondary, open or closed angle glaucoma, diagnosed by meeting the following criteria: * signs of structural damage: thinning of the optical nerve or peripapillary hemorrhage or decrease in the nerve fiber layer that can be seen by oct. * signs of functional damage: 3 points outside 95% of the normal limit on the visual field pattern deviation graph. 2. there must be at least 3 reliable visual fields prior to the start of the study. 3. patients between 50 and 75 years old, homogeneously distributed among the groups. 4. glaucoma with functional and structural damage. * medium grade, mean deviation (md) between -4 and -20 db. * in at least one eye. exclusion criteria: 1. treatment with some other vitamin or nutraceutical preparation. 2. any pathology that can alter the visual field. (neurological diseases, retinopathies, advanced cataract, patients treated with lyrica (due to the affectation it produces in the visual field)). 3. hypersensitivity to aspirin. (cross-allergic reaction has been reported in patients taking citicoline.) 4. allergic to fish protein. 5. eye surgery in the 3 months before or during the study.

Keywords: glaucoma nutraceuticals dha (docosahexaenoic acid) citicoline
clinimacs hud for t cell depletion

Conditions: x Linked Combined Immunodeficiency

Summary: this protocol is designed to enable access to related or unrelated cd34 cells manufactured using the clinimacs (miltenyi) under the hud designation for patients needing t cell depleted allogeneic grafts for hematopoietic stem cell transplant (hsct). this will include patients with inherited immunodeficiency disorders as well as patients with malignancies, bone marrow failure, and other rare diseases amenable to hsct. finally, patients with poor graft function and graft versus host disease(gvhd) after a previous hsct may require a boost of t-cell depleted donor peripheral blood stem cell (pbscs) or bone marrow cells that are cd34 selected using the clinimacs device enrollment by invitation only


Eligibility criteria:
inclusion criteria: severe combined immune deficiency need for stem cell boost exclusion criteria: n/a
the effect of reiki on hopelessness level

Conditions: Oncology Patients

Summary: this quasi-experimental study aims to examine the effect of reiki on the level of hopelessness in oncology patients. the study was conducted at i̇zmir tepecik training and research hospital with 32 patients in both experimental and control groups. patients performed reiki daily for a week following each chemotherapy session for 4 cycles. data were collected using the "individual information form" and the "beck hopelessness scale" through face-to-face and telephone interviews. ethical approval was obtained, and data were analyzed using spss.

reiki is considered a complementary and alternative therapy method that can be effective in coping with such emotional challenges and enhancing psychological well-being. it is thought that reiki practices, by regulating the flow of energy and providing deep relaxation, can reduce individuals' levels of hopelessness and improve overall quality of life. this study will investigate the effect of reiki practices on the levels of hopelessness in oncology patients.

Eligibility criteria:
inclusion criteria: receiving treatment at the outpatient chemotherapy unit of i̇zmir tepecik training and research hospital university of health sciences, diagnosed with cancer, aged 18 and over, willing to participate in the research exclusion criteria: not willing to participate in the research, having communication problems

Keywords: reiki; oncology; hopelessness
venetoclax and dexamethasone for newly diagnosed light-chain amyloidosis with translocation (11;14)

Conditions: Light Chain (AL) Amyloidosis; CCND1 Translocation; Venetoclax

Summary: venetoclax is considered as a promising agent for light-chain (al) amyloidosis due to the high percentage of t(11;14). several retrospective studies showed venetoclax-based therapy could induce rapid and profound hematologic response in al patients with favorable safety profile. as an oral agent with encouraging data, it is worth to prospectively evaluate the efficacy and safety of venetoclax in untreated al amyloidosis patients.


Eligibility criteria:
inclusion criteria: * biopsy proved treatment-naïve al amyloidosis * fluorescence in situ hybridization (fish) t(11;14) ≥ 10% * dflc \> 50mg/l exclusion criteria: * co-morbidity of uncontrolled infection * co-morbidity of other active malignancy * co-diagnosis of multiple myeloma or waldenstrom macroglobulinemia * co-morbidity of grade 2 mobitz ii or grade 3 atrioventricular block (expect for those with implanted pacemaker) * co-morbidity of sustained or recurrent nonsustained ventricular tachycardia * seropositive for human immunodeficiency virus * hepatitis b virus (hbv)-dna \> 1000 copies/ml * seropositive for hepatitis c (except in the setting of a sustained virologic response) * systemic treatment with moderate or strong cytochrome p450 3a （cyp3a） inducers, moderate or strong cyp3a inhibitors within 7 days prior to the first dose of study drug * neutrophil \<1×10e9/l，hemoglobin \< 8g/dl，or platelet \< 100×10e9/l. * severely compromised hepatic or renal function: alanine transaminase (alt) or aspertate aminotransferase (ast) \> 2.5 × upper limit of normal (uln), total bilirubin \> 3 × uln，egfr \< 15 ml/min, or receiving renal replacement therapy
preventing depression in people with epilepsy: an extension of project uplift

Conditions: Epilepsy; Depressive Symptoms; Depression; Seizure Disorder

Summary: project uplift, a home-based treatment for depression in people with epilepsy, was designed to be delivered to groups by telephone or web. the project uplift intervention materials were demonstrated to be effective in treating depression among people with epilepsy in georgia. this project will assess whether the materials are also effective for preventing depression among people with epilepsy, and will extend the project beyond georgia to michigan, texas, and washington.

the study is a pilot test of project uplift for depression prevention during which the acceptability and estimates of effectiveness of the intervention, presented in the web and telephone modes, are assessed.

Eligibility criteria:
inclusion criteria: * diagnosis of epilepsy * at least three months post initial diagnosis of epilepsy and either on medication or permission of the physician * symptoms of depression, but absence of moderate-to-severe depression, (8 \< ces-d \< 27) * 21 years of age and older * english speaking * had access to a telephone * mentally stable, as determined by a score of \> 26 on the telephone mini-mental status exam (t-mmse) * willing to participate * willing to complete assessments three times exclusion criteria: * no diagnosis of epilepsy * less than 3 months since diagnosis of epilepsy * no depressive symptom (ces-d \<8) * severe depression (ces-d \> 27) * suicidal ideation * previous participation in project uplift

Keywords: epilepsy seizure cognitive behavioral therapy mindfulness depression depressive symptoms prevention coping skills quality of life telehealth phone intervention internet-based intervention
self-care in older frail persons with heart failure intervention

Conditions: Self Care; Heart Failure; Frailty

Summary: the overall purpose of the randomized controlled study is to evaluate the effects of physical exercise, nutrition and symptom management on physical capacity in older, frail persons with heart failure.

the randomized controlled study will be conducted in order to evaluate the effects of individual needs of physical exercise, nutrition, and symptom management in patients with heart failure who are frail and older. patients discharged from a geriatric hospital will be recruited and included after informed consent. two weeks after hospital discharge patients are randomized to intervention or control group. the intervention period is 3 months. with support from a physioterapeut, dietician and a registered nurse, the intervention will be performed in the participants´ home. once a week participants will come to the hospital for physical exercise led by a physiotherapist. once a week or every other week participants will meet a dietician and a nurse. data will be collected at baseline, and 3 and 6 months after baseline. data consist of e.g. study flow description, number of eligible patients, number of drop-outs, patients sociodemographic- and clinical data, physical function and performance, nutritional status, symptom burden, self-care, appetite, thirst, health-related quality of life. at 12 months after baseline, data will be collected on hospital admissions, reasons for hospital admissions, length of stay and mortality.

Eligibility criteria:
inclusion criteria: * patients at geriatric clinic * diagnosed with heart failure (independent of ejection fraction (ef): both patients with preserved ef or reduced ef can be included * new york heart association functional class ii - iii * clinical frailty level 4-6 (moderate frailty) * discharge from hospital to home exclusion criteria: * new york heart associacion functional class i or iv * clinical frailty level 1-3 (no/mild frailty) and 7-9 (severe frailty) * the patient is unable to perform gait tests due to visual (see a tv screen at a 3 meter distance), cognitive (assessed by nurse or doctor) or motor impairment (the patient should be able to stand up from sitting and have the ability to walk with or without a walker or other walking aid). * the patient is unable to follow instructions (assessed by nurse or doctor)

Keywords: self care heart failure symptom management exercise nutrition
hepatic function in alcoholics following 5 days of acetaminophen dosing

Conditions: Alcohol Related Disorders

Summary: the study objective was to determine if liver injury develops in alcoholic patients during or following 5 days of therapeutic acetaminophen dosing. volunteers were recruited from two community detoxification centers to take either acetaminophen (4g/day) or placebo for 5 consecutive days. all subjects were monitored an additional two days following the dosing period. the primary measures were aminotransferase measures taken at baseline and days 2, 4, 6 and 7. we hypothesized that there would be no difference in aminotransferase means between the groups at any study period.


Eligibility criteria:
inclusion criteria: * 18 years and older * admitted to participating detox facility with a positive bal at the time of admittance * signed a written informed consent exclusion criteria: * serum acetaminophen level greater than 20 mcg/ml * serum ast or alt levels greater than 200 iu/l * inr greater than 1.5 * if female, positive for beta-subunit of chorionic gonadotropin (beta-hcg) * clinically intoxicated, psychiatrically impaired or unable to give informed consent * known hypersensitivity to acetaminophen * history of ingesting more than four grams of apap per day for any of the four days preceding study enrollment * currently enrolled in another trial or had been enrolled in another trial in the preceding three months.

Keywords: acetaminophen alcohol liver injury
pharmacist - physician collaborative approach to the management of metabolic syndrome

Conditions: Metabolic Syndrome

Summary: this study devised an experimental focused pharmaceutical care program, allowed a clinical pharmacist to work in a physician office to assess and manage patients' metabolic syndrome status and its individual components. this study described the clinical benefits of physician- clinical pharmacist interaction in achieving improved glycemic control, lipid and blood pressure measurements, involving medication, diet, physical activity and patient heath care counseling.

a single blinded prospective randomized controlled trial conducted in family medicine outpatients clinics in jordan. the study enrolled 199 patients met the national cholesterol education program adult treatment panel iii (ncep/atpiii) criteria for the diagnosis of ms upon the time of enrollment. patients were randomized into: 110 participants into the intervention arm (pharmacist-physician collaborative approach) and 89 into the control arm (physician only team). only patients in the intervention arm were provided pharmacist recommendations and pharmaceutical care counseling.

Eligibility criteria:
inclusion criteria: * meeting at least 3 of the 5 criteria for the national cholesterol education program adult treatment panel iii (ncep/atpiii) for the diagnosis of metabolic syndrome upon the time of enrollment. : 1. abdominal circumference \>102 cm in males or \>88 cm in females. 2. hdl cholesterol \< 40 mg/dl for males or \< 50 mg/dl for females. 3. triglycerides ≥ 150 mg/dl. 4. blood pressure ≥ 130/85 mmhg or receiving hypertension treatment. 5. baseline glycemia ≥ 110 mg/dl. exclusion criteria: 1. patients with hypertensive urgency or emergency with bp more than (180/110). 2. patients with recent stroke or myocardial infraction (within past 6 months). 3. patients with class iii or iv chronic heart failure (chf). 4. patients with unstable angina. 5. patients with serious renal or hepatic disease. 6. pregnant patients. 7. patients with dementia or cognitive impairment. 8. if the patient is unable to provide informed written consent.
multitissular effect of vertical mobilization using the exoskeleton atalantetm in neurological chair- or bed-bound patients

Conditions: Neurologic Disorder

Summary: background and aim: sustained bed rest impairs many bodily functions. verticalization restores gravitational challenge and the use of several organs. the atalante™ exoskeleton (wandercraft) is the only self-balanced exoskeleton, which allows walking without canes. we assessed multi-tissular effects of mobile reverticalization using atalante™ in neurological bed- or wheelchair-bound patients. methods: observational cohort study. inclusion criteria: bed- or wheelchair-bound for \>2 weeks and \<1 hour per day of stance, due to a central neurological disorder. sessions with exoskeleton were 3/week, integrated in routine care. data collected at baseline and after eight weeks (w8) included: cardiovascular (echocardiography, ekg, blood pressure lying and standing), pulmonary (spirometry), bone (densitometry, biochemical markers), bowels (daily stool frequency, bristol stool scale), urinary (urinary flow, postmictional residual volume, urinary symptom profile questionnaire, usp), cognitive (trail making test, tmt-b), anxiety and depression (had), and quality of life (sf12). results will be presented at the end of the study.


Eligibility criteria:
inclusion criteria: * inpatient in neurorehabilitation * neuroligical lesion * chair or bed bound more than 23h/24h and more than 2 weeks * over 18 years old exclusion criteria: * spasticity over 3 on mas * any porotic fracture * heel pressure sore * height \> 150 cms, \> 190 cms * weight \ 90 kgs * recent thoracic or abdominal surgery * pregnancy * range of motion aloud to use the exoskeleton
treating pcos with digital intervention vs. metformin

Conditions: Polycystic Ovary Syndrome

Summary: with the change in environment and lifestyle, and the improvement of people's understanding of pcos, the incidence of pcos is increasing worldwide. according to statistics, the prevalence of pcos in premenopausal women is as high as 5-20%. lifestyle interventions are the main treatment option for patients with pcos. in addition, research has shown that digital therapy can effectively improve behavior changes in diet, exercise, and medication adherence, predict disease progression, reduce the frequency of disease-related symptoms, and promote effective disease management. this study aimed to investigate the efficacy of digital intervention versus traditional metformin monotherapy in patients with pcos.

this study developed a mini-program that combined diet, exercise, sleep, and mood interventions for pcos women.

Eligibility criteria:
inclusion criteria: female aged 18- 45; meet rotterdam criteria; insulin resistance exclusion criteria: women who are pregnant or have a pregnancy plan within six months; congenital adrenocortical hyperplasia; hyperprolactinemia; hyperthyroidism or hypothyroidism; abnormal liver function (≥ 3 times the upper limit of the normal range); abnormal renal function (gfr\<60ml/min/1.73m2); adrenal or ovarian tumors secreting androgens; used contraceptives, metformin, pioglitazone, and antidepressant medication in the last 3 months.
ruxolitinib in primary myelofibrosis and secondary to essential thrombocythemia or polycythemia vera

Conditions: Myelofibrosis; Primary Myelofibrosis; Secondary Myelofibrosis

Summary: the study is observational multicenter retrospective and prospective cohort study of patients with primary or secondary myelofibrosis who have initiated therapy with ruxolitinib, prescribed as part of the normal course of care and completely independent of study participation. the primary purpose is to determine the impact of clinical and laboratory characteristics of myelofibrosis on the prognosis of patients treated with ruxolitinib, understood as long-term survival.

the study is observational multicenter retrospective and prospective cohort study of patients with primary or secondary myelofibrosis who have initiated therapy with ruxolitinib, prescribed as part of the normal course of care and completely independent of study participation. laboratory tests and histological, cytogenetic, molecular, and radiological investigations performed by the patient and collected for study will be conducted in accordance with clinical practice, independent of the patient's participation in the study. in particular. data on systemic symptoms and splenomegaly will be collected at diagnosis and disease reassessments performed in the context of normal clinical practice. the minimum planned duration of individual patient observation is 3 months and the planned duration of the study is 10 years.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * patients diagnosed with primary myelofibrosis or secondary to essential thrombocythemia/polycythemia vera who are being treated or have been treated with ruxolitinib therapy in accordance with normal clinical practice. * availability of data on clinical history prior to initiation of ruxolitinib therapy * obtaining informed consent for data collection and processing exclusion criteria: * none

Keywords: safety efficacy
long term follow-up grafted huntington's disease patients

Conditions: Huntington Disease

Summary: long-term follow-up of huntington's disease patients treated with intrastriatal allografts is essential to assess the benefit/risk ratio of grafts as well as their effectiveness. indeed, some patients are likely to develop adverse effects and the impact of alloimmunisation phenomena remains to be explored.

the aim is to create a specific cohort of transplant patients, to homogenise their follow-up methods, to collect all the patient data (medical, paramedical, imaging, biological) acquired from the end of their participation in mig-hd'study (foetal striatal allografting in huntington's disease: a multicentre, randomised, delayed start, phase 2 open-label cell therapy trial) until the last possible follow-up of the last patient in the study

Eligibility criteria:
inclusion criteria: * adult patients transplanted under the mig-hd protocol * information and informed consent from patients or their representative * affiliation with a social security scheme or beneficiary exclusion criteria: * patient under ame * patient unable to express consent and not subject to legal protection * knowned pregnancy or breastfeeding woman

Keywords: grafted patients long term follow-up
intravitreal ranibizumab in recurrent rop

Conditions: Retinopathy of Prematurity

Summary: a retrospective study included reviewing of medical records of preterm babies who were admitted in neonatal intensive care unit (nicu) of mansoura university children hospital (much) or referred from nearby hospitals for rop screening during the period from march 2013 to february 2020.

retinopathy of prematurity was diagnosed and classified according to the international classification of rop. data of the patients who received ivr for type 1 rop or aggressive posterior rop (ap-rop) according to early treatment rop study (etrop) were collected. intravitreal ranibizumab injection was performed as follows; topical anesthetic drop was applied, standard aseptic eye preparation with 5% betadine was performed, a lid speculum was inserted and intravitreal injection of 0.25 mg/0.025 ml ranibizumab with a 30-gauge needle 1.5mm from limbus was given. in case of bilateral rop, both eyes are injected in the same session. infants were examined a day after the procedure and weekly thereafter until full vascularization of the retina was observed. rop reactivation was defined as any of the following: recurrent plus disease, recurrent neovascularization, or reformation of ridge despite treatment . once recurrence was determined, second injection of ivr (0.25mg/0.025ml) was given to patients or surgery was performed if progressed to stage 4 or 5. all treated infants were examined until complete regression of rop and full retinal vascularization.

Eligibility criteria:
inclusion criteria: * patients received ivr for type 1 rop or aggressive posterior rop (ap-rop) according to early treatment rop study (etrop) and developed recurrence of rop exclusion criteria: -
treatment of chronic postherpetic pain with autologous fat grafting - a rct

Conditions: Postherpetic Neuralgia; Shingles; Varicella Zoster; Herpes Zoster; Chronic Pain

Summary: this randomized clinical trial investigates the possible beneficial effect of autologous fat grafting on postherpetic neuralgia.

herpes zoster (hz), is a condition caused by varicella-zoster virus (vzv), the disease is caused by reactivation of a latent vzv-infection in the sensory ganglia. clinically the condition is characterized by a painful, unilateral, vesicular rash. pain is the most prominent symptom in around 90% of patients. in 10% of patients, this pain remains and becomes chronic. post-herpetic neuralgia is a chronic pain syndrome that occurs after the dermal manifestation disappears. treatment is complex and mainly topical or systemic. for many patients, this is not sufficient and they live with constant pain. autologous fat grafting has shown promise in treating several different painful conditions such as post-mastectomy pain syndrome, painful scars, etc. our previous pilot study (nct03584061) investigating the effect of autologous fat grafting on phn, showed a marked reduction in pain with half of the patients being pain-free after the procedure. the aim of this study is to test the hypothesis that autologous fat grafting is more effective than a sham operation in treating phn.

Eligibility criteria:
* inclusion criteria: * age over 18 * pain in area of former vzv-infection. * pain present over 3 months after reactivation of vzv and is present at least 4 days a week and of intensity \>3 on the vas-scale * exclusion criteria: * psychiatric illness that could potentially affect the study.

Keywords: chronic pain postherpetic neuralgia